Most people believe a clinical trial fails because of something that happens during the study. A protocol deviation. A regulatory delay. A recruitment slowdown. But the truth is far simpler. Most trials fail long before the first participant ever steps into a site. One of the most critical choices a sponsor has to make is […]
Early-phase clinical trials, particularly Phase I and early Phase II, are often seen as exploratory stepping stones. Yet, what happens at these stages can determine the fate of an entire drug development program. At the heart of these early decisions lies biostatistics: the scientific foundation that transforms raw observations into meaningful insight. Unfortunately, many sponsors underestimate its importance. Poor biostatistical […]
Imagine investing millions in a clinical trial only to face rejection from regulators because of data inconsistencies that are completely avoidable. Even worse, consider the risks to patient safety if adverse events are overlooked due to weak statistical planning. Unfortunately, this scenario is not rare. Studies show that nearly 90% of clinical trials fail to […]
Oncology is one of the most complex and resource-heavy areas of clinical research. Unlike other therapeutic domains, cancer trials must navigate rapidly evolving treatment methods, complex trial designs, and significant safety concerns. Often while racing against time for patients with life-limiting conditions. Here, generalized trial management approaches often fall short. Specialized clinical trial monitoring services […]
